AUTHORS
Joan Park, MD, Erica Riddick, MD2, Raquel Sofia Sandoval, MD, MPP3, Lydia Pecker, MD4, Elizabeth Prince, DO5
AFFILIATIONS
1 Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
2 Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
3 Indian Health Service, Tuba City, Arizona, United States
4 Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
5 Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
ABSTRACT
Introduction – Buprenorphine, a partial opioid agonist, is increasingly used for chronic pain in sickle cell disease (SCD). Buprenorphine is considered a safer alternative to full agonist opioids due to a “ceiling effect,” reducing the risk of respiratory depression and overdose while still providing analgesia. Growing literature indicates that buprenorphine reduces acute care visits and improves pain control and function for adults with SCD. Previous work from our group demonstrated transition from full opioid agonists to buprenorphine requires patient engagement and buy-in. However, there is a dearth of patient education resources tailored specifically to people with SCD rather than opioid use disorder. The purpose of this study was to develop a patient-centered education tool that addresses common questions about the purpose, safety profile, and efficacy of buprenorphine for chronic pain in SCD.
Methods – This qualitative study was approved by the Johns Hopkins Institutional Review Board. Adults with SCD and sickle cell center clinicians were recruited from August 2024 to May 2026 using a convenience sampling approach. Patient participants were approached during routine clinical appointments in the sickle cell center. Clinician participants were invited to participate by email. Inclusion criteria were age ≥ 18 years, English-speaking, and ≥ 5th grade literacy level. The research protocol followed the Standards for Reporting Qualitative Research.
The study team developed the patient education tool using existing literature on buprenorphine, chronic pain, and SCD. The tool was shared with participants during semi-structured interviews conducted between March 2025 and June 2026, eliciting perspectives on chronic pain, buprenorphine, and the tool itself. Interviews were recorded, transcribed, and analyzed, with feedback incorporated into three iterations of the tool.
Results – We approached 36 eligible subjects, 30/36 consented, and 17/36 completed interviews; 11 patients and 6 clinicians. Patients were a mean age of 32 years, 73% women, 45% reported chronic pain, and 27% had taken buprenorphine. All clinicians worked at a sickle cell center and had experience prescribing buprenorphine for chronic pain; 50% were physicians and 50% were advanced practice providers.
Two themes on buprenorphine and two on the education tool were identified from both patient and clinician participants: 1) Buprenorphine is promising, but trustworthy information is needed. Patient participants with chronic pain and clinicians noted that buprenorphine could be helpful but wanted to know more about how to use it. 2) Stigma and fear of the unknown are barriers to buprenorphine; participants shared negative experiences related to pain, SCD, and all opioids. They also noted that overcoming stigma and uncertainty were important steps in deciding to try buprenorphine. 3) The education tool is informative and SCD-specific. Participants appreciated the SCD focus and acknowledged the need to balance the amount of information in the tool with patient accessibility. There were requests for additional tools about buprenorphine induction for both patients and clinicians. 4) The tool should be shared intentionally and as part of a patient-clinician discussion. The tool was identified as a component of larger discussions about approaches to treating chronic pain between a patient and a trusted clinician.
Discussion – Across clinician and patient interviews, the buprenorphine education tool was generally well received as a clear, patient-friendly, and supportive resource. Both groups saw buprenorphine as a promising option for chronic sickle cell pain, though stigma and uncertainty remain significant barriers. Practical instructions about administration and how buprenorphine impacted acute pain management were among the highest-priority educational needs of patients. The strongest recommendation from both clinicians and patients was intentionally sharing the tool during a clinician-patient discussion, rather than passive distribution.
Participants suggested additional tools for the initiation of buprenorphine for both patients and clinicians. The small sample, with patients all from a single Sickle Cell Center may limit generalizability. As evidence and clinical experience grow with buprenorphine for chronic pain in SCD, the current version of the tool may need updates.
DISCLOSURES
Elizabeth Prince, DO: No relevant conflicts of interest to declare.